blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2542238

EP2542238 - COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.06.2016
Database last updated on 14.09.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
Onyx Therapeutics, Inc.
249 E. Grand Avenue
South San Francisco, CA 94080 / US
[2013/02]
Inventor(s)01 / SHENK, Kevin D.
565 Arastradero Road
203
Palo Alto California 94306 / US
02 / PARLATI, Francesco
1035 York Street
San Francisco California 94110 / US
03 / BENNETT, Mark K.
9 Fieldbrook Place
Moraga California 94556 / US
 [2013/02]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2015/33]
Former [2014/02]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Former [2013/02]Coehn, Markus
Fish & Richardson P.C.
High Light Business Towers
Mies-van-der-Rohe-Strasse 8
80807 München / DE
Application number, filing date11715320.501.03.2011
[2015/33]
WO2011US26629
Priority number, dateUS20100309366P01.03.2010         Original published format: US 309366 P
[2013/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011109355
Date:09.09.2011
Language:EN
[2011/36]
Type: A1 Application with search report 
No.:EP2542238
Date:09.01.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 09.09.2011 takes the place of the publication of the European patent application.
[2013/02]
Type: B1 Patent specification 
No.:EP2542238
Date:12.08.2015
Language:EN
[2015/33]
Search report(s)International search report - published on:EP09.09.2011
ClassificationIPC:A61K31/4045, A61K31/5375, C07D209/20, C07D295/104, A61P37/00, A61P35/00, A61P29/00, A61P31/00, A61P25/00, C07F5/04, C07K5/065
[2013/02]
CPC:
A61P3/04 (EP); A61K31/4045 (KR); C07K5/0827 (US);
A61K31/5375 (KR); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
C07D209/20 (EP,KR,US); C07D241/24 (EP,US); C07D295/104 (EP,US);
C07D303/36 (EP,US); C07D405/12 (EP,US); C07F5/04 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/02]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERBINDUNGEN ZUR IMMUNPROTEASOMHEMMUNG[2013/02]
English:COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION[2013/02]
French:COMPOSÉS POUR INHIBITION DE L'IMMUNOPROTÉASOME[2013/02]
Entry into regional phase01.10.2012National basic fee paid 
01.10.2012Designation fee(s) paid 
01.10.2012Examination fee paid 
Examination procedure01.10.2012Examination requested  [2013/02]
24.04.2013Amendment by applicant (claims and/or description)
10.07.2013Despatch of a communication from the examining division (Time limit: M06)
10.01.2014Reply to a communication from the examining division
09.05.2014Despatch of a communication from the examining division (Time limit: M04)
19.09.2014Reply to a communication from the examining division
31.03.2015Communication of intention to grant the patent
02.07.2015Fee for grant paid
02.07.2015Fee for publishing/printing paid
02.07.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.07.2013
Opposition(s)13.05.2016No opposition filed within time limit [2016/29]
Fees paidRenewal fee
27.03.2013Renewal fee patent year 03
27.03.2014Renewal fee patent year 04
10.03.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.03.2011
AL12.08.2015
AT12.08.2015
BE12.08.2015
BG12.08.2015
CY12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MK12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
SM12.08.2015
TR12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
MT31.03.2016
[2018/47]
Former [2018/38]HU01.03.2011
AT12.08.2015
BE12.08.2015
BG12.08.2015
CY12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MK12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
SM12.08.2015
TR12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
MT31.03.2016
Former [2018/31]HU01.03.2011
AT12.08.2015
BE12.08.2015
CY12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MK12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
SM12.08.2015
TR12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
MT31.03.2016
Former [2018/29]HU01.03.2011
AT12.08.2015
BE12.08.2015
CY12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MK12.08.2015
MT12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
SM12.08.2015
TR12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
Former [2018/28]HU01.03.2011
AT12.08.2015
BE12.08.2015
CY12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MK12.08.2015
MT12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
SM12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
Former [2017/47]AT12.08.2015
BE12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
MT12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
Former [2017/07]AT12.08.2015
BE12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
IE01.03.2016
LU01.03.2016
Former [2017/03]AT12.08.2015
BE12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
LU01.03.2016
Former [2016/49]AT12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
MC12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
LU01.03.2016
BE31.03.2016
Former [2016/47]AT12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
LU01.03.2016
BE31.03.2016
Former [2016/36]AT12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SI12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
BE31.03.2016
Former [2016/23]AT12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RO12.08.2015
RS12.08.2015
SE12.08.2015
SK12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/22]AT12.08.2015
CZ12.08.2015
DK12.08.2015
EE12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/21]AT12.08.2015
DK12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
IT12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/20]AT12.08.2015
DK12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/14]AT12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
LT12.08.2015
LV12.08.2015
NL12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/11]AT12.08.2015
ES12.08.2015
FI12.08.2015
HR12.08.2015
LT12.08.2015
LV12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/10]ES12.08.2015
FI12.08.2015
HR12.08.2015
LT12.08.2015
LV12.08.2015
PL12.08.2015
RS12.08.2015
SE12.08.2015
NO12.11.2015
GR13.11.2015
IS12.12.2015
PT14.12.2015
Former [2016/09]FI12.08.2015
LT12.08.2015
LV12.08.2015
NO12.11.2015
GR13.11.2015
Former [2016/08]LT12.08.2015
NO12.11.2015
Former [2016/07]LT12.08.2015
Cited inInternational search[X]WO2006099261  (UNIV NORTH CAROLINA [US], et al) [X] 1,6-12 * the whole document * * Compound; page 8, line 18 *;
 [YA]WO2006086600  (CEPHALON INC [US], et al) [Y] 14,24-32 * the whole document * * page 48, line 8 - line 22 * * page 52, line 7 - line 10 * [A] 16-18;
 [XP]WO2010036357  (MILLENNIUM PHARM INC [US], et al) [XP] 1-3,5-9,11-13,24-32 * page 19 - page 20; compounds 16, 22 *;
 [XP]WO2010145376  (UNIV BEIJING [CN], et al) [XP] 1,5-8,11-13,15,19,24-32 * the whole document * * compounds 5a-j, 6a-j *
 [XAY]  - ZHU Y ET AL, "Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 17, no. 19, doi:DOI:10.1016/J.BMC.2009.08.023, ISSN 0968-0896, (20091001), pages 6851 - 6861, (20090820), XP026601532 [X] 1-3,5-8,11-13,15,19,24-32 * the whole document * * page 6854 - page 6855; examples 6a-m, 7a-m * [A] 9,10,17,18,21-23 [Y] 4,14,16,20

DOI:   http://dx.doi.org/10.1016/j.bmc.2009.08.023
 [X]  - WATANABE T ET AL, "Synthesis of boronic acid derivatives of tyropeptin: Proteasome inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 8, doi:DOI:10.1016/J.BMCL.2009.02.117, ISSN 0960-894X, (20090415), pages 2343 - 2345, (20090304), XP026079469 [X] 1,8-13,24-32 * the whole document * * page 2344; examples 3a-c, 13a-c *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2009.02.117
 [X]  - PIVAZYAN, A.D.; MATTESON, D.S.; FRABRY-ASZTALOS, L.; SINGH, R.P.; LIN, P-F.; BLAIR, W.; GUO, K.; ROBINSON, B.; PRUSOFF, W.H., "Inhibition of HIC-1 Protease by a Boron-Modified Polypeptide", BIOCHEMICAL PHARMACOLOGY, (2000), vol. 60, pages 927 - 936, XP002638798 [X] 1,27,32 * the whole document * * page 928; figure 2; compounds 4a-e *

DOI:   http://dx.doi.org/10.1016/S0006-2952(00)00432-9
 [Y]  - ZHU, Y.; ZHAO, X.; ZHU, G.; LI, Y.; MA, Y.; YUAN, Y.; YANG, J.; HU, Y.; AI, L.; GAO, Q., "Design, Synthesis, Biological Evaluation, and Structure - Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Undertanding of the SAR of a-Amino Acid Boronates", JOURNAL OF MEDICINAL CHEMISTRY, (2009), vol. 52, pages 4192 - 4199, XP002638799 [Y] 4,16,20,24-32 * the whole document * * page 4195; table 1; compounds 22, 24, 33 *

DOI:   http://dx.doi.org/10.1021/jm9005093
 [YA]  - ZHU Y Q ET AL, "3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 44, no. 4, doi:DOI:10.1016/J.EJMECH.2008.07.019, ISSN 0223-5234, (20090401), pages 1486 - 1499, (20080724), XP026003082 [Y] 20,24-32 * the whole document * * Compounds MG273, MG285, MG286, MG292, MG300, MG307-309; MG312, MG315, MG318, MG322, MG324, MG387, MG306, MG317, MG328, MG346, MG353, MG329; page 1488 - page 1494 * [A] 21,22

DOI:   http://dx.doi.org/10.1016/j.ejmech.2008.07.019
by applicantWO9810779
 US5340736
    - FOX, WHITESELL, Organic Chemistry, JONES AND BARTLETT PUBLISHERS, (1994), pages 177 - 178
    - "Peptides and Mimics, Design of Conformationally Constrained", HRUBY, BOTEJU, Molecular Biology and Biotechnology: A Comprehensive Desk Reference, VCH PUBLISHERS, (1995), pages 658 - 664
    - CASCIO ET AL., EMBO J, (2001), vol. 20, pages 2357 - 2366
    - EGERER ET AL., ARTHRITIS RHEUM, (2006), vol. 54, pages 1501 - 8
    - MENG ET AL., PNAS, (1999), vol. 96, pages 10403 - 10408
    - MACARY ET AL., PNAS, (2001), vol. 98, pages 3982 - 3987
    - QURESHI, N. ET AL., J. IMMUN., (2003), vol. 171, pages 1515 - 1525
    - PAUGAM ET AL., TRENDS PARASITOL., (2003), vol. 19, no. 2, pages 55 - 59
    - GONZALES ET AL., ARCH. MED. RES., (1997), vol. 28, pages 139 - 140
    - SZALAY ET AL., AM J PATHOL, (2006), vol. 168, pages 1542 - 52
    - YU, LAI, J VIROL, (2005), vol. 79, pages 644 - 648
    - SIMSEK ET AL., J VIROL, (2005), vol. 79, pages 12914 - 12920
    - KHAN ET AL., J IMMUNOL, (2001), vol. 167, pages 6859 - 6868
    - TAWA ET AL., JCI, (1997), vol. 100, pages 197 - 203
    - ACHARYYA ET AL., JCI, (2004), vol. 114, pages 370 - 378
    - LECKER ET AL., FASEB J, (2004), vol. 18, pages 39 - 51
    - PALOMBELLA ET AL., CELL, (1994), vol. 78, pages 773 - 785
    - TRAENCKNER ET AL., EMBO J., (1994), vol. 13, pages 5433 - 5441
    - CIECHANOVER, A., CELL, (1994), vol. 79, pages 13 - 21
    - KUMATORI ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 7071 - 7075
    - GAN ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 5565 - 5572
    - MISHTO ET AL., NEUROBIOL AGING, (2006), vol. 27, pages 54 - 66
    - DIAZ-HERNANDEZ ET AL., J NEUROSCI, (2003), vol. 23, pages 11653 - 1161
    - GARRETT, 1. R. ET AL., J. CLIN. INVEST., (2003), vol. 111, pages 1771 - 1782
    - BERGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - J. MED. CHEM., (2008), vol. 51, page 1068
    - STEIN ET AL., BIOCHEM., (1996), vol. 35, pages 3899 - 3908
 US20070820490
 US20000569748
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.